RxDoctor Payments Data

Jennifer Burman

Family · Minot, NDNPI 1083137756

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 247 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $931, 3.3 times the $280 reported in 2021. Among family clinicians in ND with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,400in general payments, 2019–2025

Across 247 payments — averaging $13.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$786
  • Lilly USA, LLC$653
  • Novo Nordisk$552
  • Amgen$547
  • Takeda Pharmaceuticals U.S.A., Inc.$120
  • Exact Sciences$95
  • plus $647 from 19 others

What the payments were for

  • Food & beverage$3,400100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,400 in reported general payments places this provider in the 95th percentile of 496 family providers in North Dakota.

See all family providers in North Dakota

Medicare billing

Part B allowed, 2024
$31,913
Medicare patients
92
Services billed
577

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide20$37,803
EliquisApixaban13$16,213
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$1,852
Levothyroxine Sodium100$1,232
Metformin Hcl ErMetformin Hcl70$1,208
SynthroidLevothyroxine Sodium11$1,198
Atorvastatin Calcium123$1,188
Ventolin HfaAlbuterol Sulfate18$1,036
Metoprolol Succinate53$1,026
Omeprazole60$987
Albuterol Sulfate HfaAlbuterol Sulfate29$719
Pantoprazole Sodium44$705
Rosuvastatin Calcium57$688
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide39$655
Amlodipine Besylate85$607

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$552$37,80320 claims
PfizerEliquis$42$16,21313 claims
AbbVieSynthroid$786$1,19811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 496 family providers in North Dakota.

Other family in Minot

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →